Načítá se...
Bevacizumab for progressive glioblastoma multiforme: a case of treading the tightrope
Until March 2013, Bevacizumab had been funded through the National Cancer Drugs Fund (CDF) for the treatment of recurrent/progressive Glioblastoma multiforme (GBM). Although the CDF concluded at the time that there was insufficient evidence around the effectiveness of the Bevacizumab on overall surv...
Uloženo v:
| Vydáno v: | Neuro Oncol |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Oxford University Press
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5791690/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox238.094 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|